论文部分内容阅读
目的评价伏格列波糖在合并糖耐量减低老年冠心病患者中的早期干预治疗效果。方法 80例合并糖耐量减低老年冠心病患者分为对照组和试验组,各40例,对照组用阿卡波糖50 mg,每天3次,试验组口服伏格列波糖20 mg,每天3次,连续12个月。比较2组疗效及空腹血糖(FPG)、2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、胰岛素β细胞功能(HOMA-β)以及胰岛素抵抗指数(HOMA-IR)指标。结果试验组治疗后FPG、2 h PG、Hb A1c、HOMA-β、HOMA-IR指标显著低于对照组(P<0.05)。试验组合并糖耐量降低发展为2型糖尿病发生率低于对照组;试验组转化为糖耐量正常百分比高于对照组,但差异均无统计学意义(P>0.05)。试验组不良反应发生率为10.0%,显著低于对照组的22.5%(P<0.05)。结论伏格列波糖对老年冠心病合并耐糖量减低患者早期干预疗效好,能够降低患者血糖,降低心血管疾病发生率。
Objective To evaluate the effect of voglibose on early intervention in elderly patients with coronary heart disease complicated with impaired glucose tolerance. Methods Eighty patients with coronary heart disease with impaired glucose tolerance were divided into control group and trial group, 40 cases in each group. The control group received acarbose 50 mg three times a day. The test group was given oral Voglibose 20 mg daily Times, for 12 consecutive months. The curative effect and fasting blood glucose (FPG), 2 h PG, Hb A1c, HOMA-β and HOMA-IR were compared between the two groups. Results The indexes of FPG, 2 h PG, Hb A1c, HOMA-β and HOMA-IR in the experimental group were significantly lower than those in the control group (P <0.05). The incidence of type 2 diabetes mellitus was lower in the experimental group with impaired glucose tolerance than that of the control group. The percentage of normal glucose tolerance patients in the experimental group was higher than that in the control group, but the difference was not statistically significant (P> 0.05). The incidence of adverse reactions in the experimental group was 10.0%, which was significantly lower than that in the control group (22.5%, P <0.05). Conclusion Voglibose has a good effect on early intervention in elderly patients with coronary heart disease and low glycemic control, which can reduce blood glucose and reduce the incidence of cardiovascular diseases.